Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy

• Published in: Breast cancer research and treatment Vol. 183; no. 3; pp. 617 - 627
• Main Authors: Dudek, Arkadiusz Z., Liu, Li C., Fischer, James H., Wiley, Elizabeth L., Sachdev, Jasgit C., Bleeker, Jonathan, Hurley, Randolph W., Tonetti, Debra A., Thatcher, Gregory R. J., Venuti, Robert P., O’Regan, Ruth M.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.10.2020; Springer; Springer Nature B.V
• Subjects: Antitumor activity; Aspartate; Aspartate transaminase; Breast cancer; Cancer; Cancer patients; Cancer research; Clinical Trial; Cyclin-dependent kinase 4; Diarrhea; Drug therapy; Embolism; Estrogen; Estrogen receptors; Medicine; Medicine & Public Health; Metastases; Metastasis; Myalgia; NCT; NCT03201913; Oncology; Oncology, Experimental; Patients; Pharmacokinetics; Protein kinase C; Pulmonary embolism; Stroma; Toxicity; Transaminase; Tumors; Estrogen receptor; TTC-352; Phase 1 study; Refractory breast cancer

Purpose TTC-352 is a selective human estrogen receptor (ER) partial agonist developed for treatment of hormone-refractory ER + breast cancer. Methods This was an accelerated dose escalation study with the primary endpoint of maximum tolerated dose that evaluated five dose levels of TTC-352 in breast...